Mitochondrial function in Parkinson's disease

There is increasing evidence for a defect of mitochondrial respiratory chain function in Parkinson's disease. Specific NADH CoQ1 reductase (complex I) deficiency has been identified in the substantia nigra. Available evidence suggests that this defect is confined to the substantia nigra and is not present elsewhere in the parkinsonian brain. The absence of a detectable mitochondrial abnormality in the substantia nigra of patients with multiple system atrophy also suggests that the complex I deficiency in Parkinson's disease is not simply due to an artifact of neuronal degeneration. Evidence for abnormal mitochondrial function in skeletal muscle is conflicting; two studies showed multiple respiratory chain defects and one study was unable to demonstrate any deficiency. A severe deficiency of complex I activity has been found in platelet mitochondria from parkinsonian patients. This finding has not as yet been confirmed. Platelet homogenates do not show the complex I deficiency, however, suggesting that such a preparation may be too insensitive to detect the defect. The role of complex I deficiency in the events that culminate in dopaminergic cell death in Parkinson's disease remains unresolved. It is likely that if this mitochondrial defect is confirmed, it will be related to a number of other factors, including environmental agents, oxidative stress, and genetic predisposition.

[1]  J. Parks,et al.  A defect in mitochondrial electron-transport activity (NADH-coenzyme Q oxidoreductase) in Leber's hereditary optic neuropathy. , 1989, The New England journal of medicine.

[2]  P. Hebda,et al.  Subcellular fractionation of pig platelets. , 1975, Biochimica et biophysica acta.

[3]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[4]  Diana Brahams,et al.  Medicine and the Law , 1983, The Lancet.

[5]  J. Bonnar,et al.  Letter: Prostaglandins and pre-eclampsia. , 1974, Lancet.

[6]  C. Marsden,et al.  Decreased Ferritin Levels in Brain in Parkinson's Disease , 1990, Journal of neurochemistry.

[7]  Y. Kagawa,et al.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.

[8]  J. Parks,et al.  Evidence for a defect in NADH , 1990, Neurology.

[9]  J. Casida,et al.  Interaction of 1‐Methyl‐4‐Phenylpyridinium Ion (MPP+) and Its Analogs with the Rotenone/Piericidin Binding Site of NADH Dehydrogenase , 1991, Journal of neurochemistry.

[10]  J. Cooper,et al.  Quantitation of a mitochondrial DNA deletion in Parkinson's disease , 1992, FEBS letters.

[11]  C. Ward,et al.  Parkinson's disease in 65 pairs of twins and in a set of quadruplets , 1983, Neurology.

[12]  D. Wallace,et al.  Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. , 1988, Science.

[13]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[14]  I. Nonaka,et al.  A mutation in the tRNALeu(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies , 1990, Nature.

[15]  B. Summers,et al.  Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease , 1992, The Lancet.

[16]  L. Hillered,et al.  Respiratory Activity of Isolated Rat Brain Mitochondria following in vitro Exposure to Oxygen Radicals , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[18]  S. Dimauro,et al.  Recombination via flanking direct repeats is a major cause of large-scale deletions of human mitochondrial DNA. , 1990, Nucleic acids research.

[19]  R. Ramsay,et al.  Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. , 1986, Life sciences.

[20]  R. Waring,et al.  Xenobiotic metabolism in Parkinson's disease , 1989, Neurology.

[21]  B Chance,et al.  The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. , 1973, The Biochemical journal.

[22]  G. Hübscher,et al.  Specific Assays of some Phosphatases in Subcellular Fractions of Small Intestinal Mucosa , 1965, Nature.

[23]  K. Jellinger,et al.  Normal Mitochondrial Genome in Brain from Patients with Parkinson's Disease and Complex I Defect , 1990, Journal of neurochemistry.

[24]  K. Huoponen,et al.  A new mtDNA mutation associated with Leber hereditary optic neuroretinopathy. , 1991, American journal of human genetics.

[25]  Y. Mizuno,et al.  Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo , 1988, Neuroscience Letters.

[26]  M. Parisi,et al.  Impairment of mitochondrial transcription termination by a point mutation associated with the MELAS subgroup of mitochondrial encephalomyopathies , 1991, Nature.

[27]  T. Ozawa,et al.  Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in parkinson's disease , 1991, Annals of neurology.

[28]  C. Marsden,et al.  Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.

[29]  K. Jellinger,et al.  Mitochondrial DNA in Postmortem Brain from Patients with Parkinson's Disease , 1991, Journal of neurochemistry.

[30]  Douglas C. Miller,et al.  A large kindred with autosomal dominant Parkinson's disease , 1990, Annals of neurology.

[31]  H. Pall,et al.  N-methylation of pyridines in Parkinson's disease , 1991, The Lancet.

[32]  S. Dimauro,et al.  An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region , 1989, Nature.

[33]  N. Castagnoli,et al.  Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. , 1984, Biochemical and biophysical research communications.

[34]  J. A. V Pritchard,et al.  CANCER DETECTION , 1976, The Lancet.

[35]  J. Idle,et al.  Mutant debrisoquine hydroxylation genes in Parkinson's disease , 1992, The Lancet.

[36]  K. Takeshige,et al.  NADH- and NADPH-dependent formation of superoxide anions by bovine heart submitochondrial particles and NADH-ubiquinone reductase preparation. , 1979, The Biochemical journal.

[37]  F. Zoccarato,et al.  Pathways of hydrogen peroxide generation in guinea pig cerebral cortex mitochondria. , 1988, Biochemical and biophysical research communications.

[38]  K. Ohno,et al.  Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. , 1990, Biochemical and biophysical research communications.

[39]  V. Tiranti,et al.  Maternally inherited myopathy and cardiomyopathy: association with mutation in mitochondrial DNA tRNALeu(UUR) , 1991, The Lancet.

[40]  C. Marsden,et al.  A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.

[41]  A. Torroni,et al.  Mitochondrial oxidative phosphorylation defects in parkinson's disease , 1991, Annals of neurology.

[42]  W. Nicklas,et al.  4'-alkylated analogs of 1-methyl-4-phenylpyridinium ion are potent inhibitors of mitochondrial respiration. , 1990, Biochemical and biophysical research communications.

[43]  D. Wallace,et al.  Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNALys mutation , 1990, Cell.

[44]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[45]  J. Poirier,et al.  The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals. , 1985, Biochemical and biophysical research communications.

[46]  K. Ohno,et al.  Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis. , 1990, Biochemical and biophysical research communications.

[47]  A. Wilson,et al.  Paternal inheritance of mitochondrial DNA in mice , 1991, Nature.

[48]  E. Land,et al.  Chemically induced Parkinson's disease. II: Intermediates in the oxidation and reduction reactions of the 1-methyl-4-phenyl-2,3-dihydropyridinium ion and its deprotonated form. , 1989, Biochemical and biophysical research communications.

[49]  Y. Wei,et al.  Liver mitochondrial respiratory functions decline with age. , 1989, Biochemical and biophysical research communications.

[50]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[51]  C. Marsden,et al.  Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. , 1992, Brain : a journal of neurology.

[52]  J. Cooper,et al.  Mitochondrial myopathies: Clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA , 1989, Annals of neurology.

[53]  J. Cooper,et al.  Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement , 1992, Journal of neurochemistry.

[54]  N. Arnheim,et al.  Detection of a specific mitochondrial DNA deletion in tissues of older humans. , 1990, Nucleic acids research.

[55]  Y. Agid,et al.  Mitochondrial function and parental sex effect in Huntington's disease , 1990, The Lancet.